Telephone
N/A
Address
107 Rundle Street Kent Town, South Australia (SA) 5067
Description
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.09 - 0.3
Trade Value (12mth)
AU$19,011.00
1 week
10%
1 month
12.82%
YTD
-37.14%
1 year
-58.49%
All time high
0.71
EPS 3 yr Growth
46.10%
EBITDA Margin
-25.60%
Operating Cashflow
-$8m
Free Cash Flow Return
-32.00%
ROIC
-36.40%
Interest Coverage
-85.40
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
229m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 April 25 |
Investor Webinar Tuesday 6 May @2.30 PM AEST
×
Investor Webinar Tuesday 6 May @2.30 PM AEST |
29 April 25 |
March 2025 Quarterly Activities Report and Appendix 4C
×
March 2025 Quarterly Activities Report and Appendix 4C |
28 March 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
28 March 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
27 March 25 |
Change in substantial shareholding from AEF
×
Change in substantial shareholding from AEF |
25 March 25 |
Cleansing Notice
×
Cleansing Notice |
25 March 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
19 March 25 |
EYE 19 March 2025 General Meeting Results
×
EYE 19 March 2025 General Meeting Results |
04 March 25 |
Investor Webinar
×
Investor Webinar |
26 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
26 February 25 |
Half-Year Report Release
×
Half-Year Report Release |
26 February 25 |
Presentation Half- Year Financial Report
×
Presentation Half- Year Financial Report |
14 February 25 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
11 February 25 |
Change in substantial shareholding from AEF
×
Change in substantial shareholding from AEF |
07 February 25 |
Cleansing Notice
×
Cleansing Notice |
07 February 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
31 January 25 |
Quarterly Report 4C and Revenue guidance update
×
Quarterly Report 4C and Revenue guidance update |
31 January 25 |
EYE Completes $6.6 million placement
×
EYE Completes $6.6 million placement |
31 January 25 |
Investor Presentation
×
Investor Presentation |
31 January 25 |
Proposed issue of securities - EYE
×
Proposed issue of securities - EYE |
29 January 25 |
Trading Halt
×
Trading Halt |
17 December 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
28 November 24 |
Notification regarding unquoted securities - EYE
×
Notification regarding unquoted securities - EYE |
28 November 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
27 November 24 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.